JP2024525559A5 - - Google Patents
Info
- Publication number
- JP2024525559A5 JP2024525559A5 JP2024500220A JP2024500220A JP2024525559A5 JP 2024525559 A5 JP2024525559 A5 JP 2024525559A5 JP 2024500220 A JP2024500220 A JP 2024500220A JP 2024500220 A JP2024500220 A JP 2024500220A JP 2024525559 A5 JP2024525559 A5 JP 2024525559A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- ratio
- treatment
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220434P | 2021-07-09 | 2021-07-09 | |
| US63/220,434 | 2021-07-09 | ||
| US202163203444P | 2021-07-22 | 2021-07-22 | |
| US63/203,444 | 2021-07-22 | ||
| US202163263255P | 2021-10-29 | 2021-10-29 | |
| US63/263,255 | 2021-10-29 | ||
| US202163263928P | 2021-11-11 | 2021-11-11 | |
| US63/263,928 | 2021-11-11 | ||
| US202163264551P | 2021-11-24 | 2021-11-24 | |
| US63/264,551 | 2021-11-24 | ||
| US202263306028P | 2022-02-02 | 2022-02-02 | |
| US63/306,028 | 2022-02-02 | ||
| US202263269372P | 2022-03-15 | 2022-03-15 | |
| US63/269,372 | 2022-03-15 | ||
| US202263364618P | 2022-05-12 | 2022-05-12 | |
| US63/364,618 | 2022-05-12 | ||
| PCT/US2022/073576 WO2023283650A1 (en) | 2021-07-09 | 2022-07-08 | Biomarkers for alzheimer's disease treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525559A JP2024525559A (ja) | 2024-07-12 |
| JP2024525559A5 true JP2024525559A5 (https=) | 2025-07-16 |
Family
ID=83232761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500220A Pending JP2024525559A (ja) | 2021-07-09 | 2022-07-08 | アルツハイマー病治療用バイオマーカー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250163135A1 (https=) |
| EP (1) | EP4367516A1 (https=) |
| JP (1) | JP2024525559A (https=) |
| KR (1) | KR20240033017A (https=) |
| AU (1) | AU2022307687A1 (https=) |
| CA (1) | CA3225302A1 (https=) |
| CL (1) | CL2024000063A1 (https=) |
| IL (1) | IL309468A (https=) |
| MX (1) | MX2023015183A (https=) |
| TW (1) | TW202317192A (https=) |
| WO (1) | WO2023283650A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024064897A1 (en) | 2022-09-23 | 2024-03-28 | Eisai R&D Management Co., Ltd. | Methods of reducing neurodegeneration associated with neurodegenerative diseases |
| WO2025019457A1 (en) * | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025260029A1 (en) | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
| IL296992A (en) * | 2020-04-03 | 2022-12-01 | Alector Llc | Methods for using anti-trem2 antibodies |
| TWI843040B (zh) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
-
2022
- 2022-07-08 AU AU2022307687A patent/AU2022307687A1/en active Pending
- 2022-07-08 WO PCT/US2022/073576 patent/WO2023283650A1/en not_active Ceased
- 2022-07-08 EP EP22765973.7A patent/EP4367516A1/en active Pending
- 2022-07-08 CA CA3225302A patent/CA3225302A1/en active Pending
- 2022-07-08 JP JP2024500220A patent/JP2024525559A/ja active Pending
- 2022-07-08 TW TW111125802A patent/TW202317192A/zh unknown
- 2022-07-08 KR KR1020247004758A patent/KR20240033017A/ko active Pending
- 2022-07-08 IL IL309468A patent/IL309468A/en unknown
- 2022-07-08 US US18/577,174 patent/US20250163135A1/en active Pending
- 2022-07-08 MX MX2023015183A patent/MX2023015183A/es unknown
-
2024
- 2024-01-08 CL CL2024000063A patent/CL2024000063A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525559A5 (https=) | ||
| Bachurin et al. | Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention | |
| JP2025506389A5 (https=) | ||
| JP2022553329A (ja) | アルツハイマー病を治療するための抗ベータ－アミロイド抗体 | |
| TW202019471A (zh) | 阿茲海默症之治療及預防方法 | |
| McAlary et al. | Emerging developments in targeting proteotoxicity in neurodegenerative diseases | |
| JP2024525559A (ja) | アルツハイマー病治療用バイオマーカー | |
| KR20240142535A (ko) | P-tau181 수준을 사용한 치료 방법 | |
| Panza et al. | Passive tau-based immunotherapy for tauopathies | |
| Luca et al. | A Phase 1 single-ascending-dose trial in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous pnt001, a novel mid-domain tau antibody targeting cis-pT231 tau | |
| JP2020515639A (ja) | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト | |
| CN117244056A (zh) | 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物 | |
| TW202430554A (zh) | 使用ｔａｕ ＰＥＴ水平之治療方法 | |
| TW202543674A (zh) | 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途 | |
| EP4583851A1 (en) | Scyllo-inositol in combination with immunotherapeutics for the treatment of alzheimer's disease | |
| US20240352109A1 (en) | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof | |
| JP2024540294A5 (https=) | ||
| TW202325728A (zh) | 治療阿茲海默症之方法 | |
| CN117999094A (zh) | 抗Aβ初原纤维抗体的皮下配制品及其使用方法 | |
| TW202313111A (zh) | 治療阿茲海默症之方法 | |
| Shim et al. | An autopsy-proven case-based review of autoimmune encephalitis | |
| RU2024103015A (ru) | Биомаркеры для лечения болезни альцгеймера | |
| RU2024125461A (ru) | Способы лечения с применением уровня P-TAU181 | |
| US20230218604A1 (en) | PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY | |
| RU2025139087A (ru) | Способы лечения с применением антитела к протофибриллам белка а-бета |